Literature DB >> 14678347

Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygous beta2-adrenoceptor haplotypes at positions 16 and 27.

Daniel K C Lee1, Caroline E Bates, Brian J Lipworth.   

Abstract

AIMS: The relationship between beta2-adrenoceptor polymorphisms at positions 16 and 27, and the acute systemic beta2-adrenoceptor effects of inhaled salbutamol is unclear. We therefore elected to evaluate the influence of common homozygous beta2-adrenoceptor haplotypes on the acute systemic beta2-adrenoceptor effects following inhaled salbutamol in asthmatic subjects.
METHODS: An initial database search of 531 asthmatic subjects identified the two commonest homozygous haplotypes at positions 16 and 27 to be Arg16-Gln27 (12%) and Gly16-Glu27 (19%). After a 1-week washout period where all beta2-adrenoceptor agonists were withdrawn, 16 Caucasian subjects (Arg16-Gln27: n = 8 and Gly16-Glu27: n = 8) were given a single dose of inhaled salbutamol (1200 microg), followed by serial blood sampling for serum potassium, along with measurements of diastolic blood pressure and heart rate, at 5-min intervals for 20 min.
RESULTS: The two groups were well matched for age, sex, FEV1, and inhaled corticosteroid dose. Baseline values for serum potassium, diastolic blood pressure and heart rate were not significantly different comparing Arg16-Gln27 vs Gly16-Glu27. The mean +/- SEM maximum serum potassium change from baseline over 20 min was significantly greater (P = 0.04) for Arg16-Gln27: -0.37 +/- 0.05 mmol l(-1) vs Gly16-Glu27: -0.23 +/- 0.04 mmol l(-1); 95% CI for difference: -0.01 to -0.28 mmol l(-1). The maximum diastolic blood pressure change from baseline over 20 min was significantly greater (P = 0.0008) for Arg16-Gln27: -13 +/- 1 mmHg vs Gly16-Glu27: -4 +/- 2 mmHg; 95% CI for difference: -5, 14 mmHg. There was no significant difference comparing the maximum heart rate change from baseline for Arg16-Gln27: 10 +/- 3 beats min(-1) vs Gly16-Glu27: 10 +/- 3 beats min(-1).
CONCLUSIONS: Caucasian asthmatic subjects with the Arg16-Gln27 haplotype exhibited a greater systemic response to inhaled salbutamol, compared with those with the Gly16-Glu27 haplotype. The attenuated beta2-adrenoceptor response in the Gly16-Glu27 haplotype would be in keeping with increased susceptibility to prior down-regulation by endogenous catecholamines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14678347      PMCID: PMC1884414          DOI: 10.1046/j.1365-2125.2003.01978.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Comparative trough effects of formoterol and salmeterol on lymphocyte beta2-adrenoceptor--regulation and bronchodilatation.

Authors:  I Aziz; L C McFarlane; B J Lipworth
Journal:  Eur J Clin Pharmacol       Date:  1999-08       Impact factor: 2.953

2.  Photoplethysmographic assessment of pulse wave reflection: blunted response to endothelium-dependent beta2-adrenergic vasodilation in type II diabetes mellitus.

Authors:  P J Chowienczyk; R P Kelly; H MacCallum; S C Millasseau; T L Andersson; R G Gosling; J M Ritter; E E Anggård
Journal:  J Am Coll Cardiol       Date:  1999-12       Impact factor: 24.094

3.  A bolus of inhaled budesonide rapidly reverses airway subsensitivity and beta2-adrenoceptor down-regulation after regular inhaled formoterol.

Authors:  I Aziz; B J Lipworth
Journal:  Chest       Date:  1999-03       Impact factor: 9.410

Review 4.  The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma.

Authors:  S B Liggett
Journal:  J Allergy Clin Immunol       Date:  2000-02       Impact factor: 10.793

5.  Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness.

Authors:  C M Drysdale; D W McGraw; C B Stack; J C Stephens; R S Judson; K Nandabalan; K Arnold; G Ruano; S B Liggett
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

6.  Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma.

Authors:  B J Lipworth; R A Clark; D P Dhillon; R A Brown; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

7.  beta-2 Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians.

Authors:  G Gratze; J Fortin; R Labugger; A Binder; P Kotanko; B Timmermann; F C Luft; M R Hoehe; F Skrabal
Journal:  Hypertension       Date:  1999-06       Impact factor: 10.190

8.  Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.

Authors:  I Aziz; I P Hall; L C McFarlane; B J Lipworth
Journal:  J Allergy Clin Immunol       Date:  1998-03       Impact factor: 10.793

9.  Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population.

Authors:  J C Dewar; A P Wheatley; A Venn; J F Morrison; J Britton; I P Hall
Journal:  Clin Exp Allergy       Date:  1998-04       Impact factor: 5.018

10.  Concomitant inhaled corticosteroid resensitises cardiac beta2-adrenoceptors in the presence of long-acting beta2-agonist therapy.

Authors:  I Aziz; L C McFarlane; B J Lipworth
Journal:  Eur J Clin Pharmacol       Date:  1998-07       Impact factor: 2.953

View more
  6 in total

1.  Dietary sodium restriction and beta2-adrenergic receptor polymorphism modulate cardiovascular function in humans.

Authors:  John H Eisenach; Darrell R Schroeder; Tasha L Pike; Christopher P Johnson; William G Schrage; Eric M Snyder; Bruce D Johnson; Vesna D Garovic; Stephen T Turner; Michael J Joyner
Journal:  J Physiol       Date:  2006-06-01       Impact factor: 5.182

2.  beta2-Adrenoceptor gene variation and systemic vasodilatation during ganglionic blockade.

Authors:  Christiane Hesse; Darrell R Schroeder; Wayne T Nicholson; Emma C Hart; Timothy B Curry; Alan R Penheiter; Stephen T Turner; Michael J Joyner; John H Eisenach
Journal:  J Physiol       Date:  2010-06-02       Impact factor: 5.182

Review 3.  Benefit-risk assessment of long-acting beta2-agonists in asthma.

Authors:  Catherine M Jackson; Brian Lipworth
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  GENETIC VARIATION IN THE β(2)-ADRENERGIC RECEPTOR: IMPACT ON INTERMEDIATE CARDIOVASCULAR PHENOTYPES.

Authors:  C Hesse; J H Eisenach
Journal:  Curr Pharmacogenomics Person Med       Date:  2008-09

5.  Asthma in sickle cell disease: implications for treatment.

Authors:  Kathryn Blake; John Lima
Journal:  Anemia       Date:  2011-03-03

6.  Current pharmacologic approaches for prevention and treatment of bronchopulmonary dysplasia.

Authors:  Kristen Tropea; Helen Christou
Journal:  Int J Pediatr       Date:  2012-01-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.